Walter R Hsiang1, Patrick A Kenney1,2, Michael S Leapman3,4. 1. Yale University School of Medicine, New Haven, USA. 2. Department of Urology, Yale University School of Medicine, New Haven, USA. 3. Yale University School of Medicine, New Haven, USA. michael.leapman@yale.edu. 4. Department of Urology, Yale University School of Medicine, New Haven, USA. michael.leapman@yale.edu.
Abstract
PURPOSE OF REVIEW: The treatment landscape for metastatic renal cell carcinoma (mRCC) continues to evolve with ongoing advancements in systemic therapy, raising further questions about the optimal role of surgery in the management of mRCC. Herein, we provide a context and review of the recent evidence concerning the role of surgical therapy for patients with mRCC including cytoreductive nephrectomy and distant metastatectomy. RECENT FINDINGS: One randomized trial has been published in the targeted therapy era suggesting that initial systemic therapy is non-inferior to cytoreductive nephrectomy among patients with intermediate and poor-risk mRCC. Delaying cytoreductive nephrectomy until after systemic therapy may be a viable treatment approach, although a high level of evidence is lacking. Additional questions remain regarding the sequence of surgery with systemic therapy, utility of distant metastatectomy, as well as the application of these findings to the current generation of immunotherapy. Recent evidence challenges the need of upfront cytoreductive nephrectomy for unselected patients with mRCC. However, surgical therapy continues to play an important role in the management of the disease.
PURPOSE OF REVIEW: The treatment landscape for metastatic renal cell carcinoma (mRCC) continues to evolve with ongoing advancements in systemic therapy, raising further questions about the optimal role of surgery in the management of mRCC. Herein, we provide a context and review of the recent evidence concerning the role of surgical therapy for patients with mRCC including cytoreductive nephrectomy and distant metastatectomy. RECENT FINDINGS: One randomized trial has been published in the targeted therapy era suggesting that initial systemic therapy is non-inferior to cytoreductive nephrectomy among patients with intermediate and poor-risk mRCC. Delaying cytoreductive nephrectomy until after systemic therapy may be a viable treatment approach, although a high level of evidence is lacking. Additional questions remain regarding the sequence of surgery with systemic therapy, utility of distant metastatectomy, as well as the application of these findings to the current generation of immunotherapy. Recent evidence challenges the need of upfront cytoreductive nephrectomy for unselected patients with mRCC. However, surgical therapy continues to play an important role in the management of the disease.
Authors: Boris Gershman; Daniel M Moreira; Stephen A Boorjian; Christine M Lohse; John C Cheville; Brian A Costello; Bradley C Leibovich; R Houston Thompson Journal: Eur Urol Date: 2015-06-01 Impact factor: 20.096
Authors: Laurence Albiges; Tom Powles; Michael Staehler; Karim Bensalah; Rachel H Giles; Milan Hora; Markus A Kuczyk; Thomas B Lam; Börje Ljungberg; Lorenzo Marconi; Axel S Merseburger; Alessandro Volpe; Yasmin Abu-Ghanem; Saeed Dabestani; Sergio Fernández-Pello; Fabian Hofmann; Teele Kuusk; Rana Tahbaz; Axel Bex Journal: Eur Urol Date: 2019-08 Impact factor: 20.096
Authors: Nawar Hanna; Maxine Sun; Christian P Meyer; Paul L Nguyen; Sumanta K Pal; Steven L Chang; Guillermo de Velasco; Quoc-Dien Trinh; Toni K Choueiri Journal: J Clin Oncol Date: 2016-06-20 Impact factor: 44.544
Authors: Robert C Flanigan; G Mickisch; Richard Sylvester; Cathy Tangen; H Van Poppel; E David Crawford Journal: J Urol Date: 2004-03 Impact factor: 7.450
Authors: Allard Noe; Roderick E de Bruijn; Christian Blank; Simon Horenblas; John Haanen; Axel Bex Journal: World J Urol Date: 2016-02-01 Impact factor: 4.226
Authors: Robert J Motzer; Konstantin Penkov; John Haanen; Brian Rini; Laurence Albiges; Matthew T Campbell; Balaji Venugopal; Christian Kollmannsberger; Sylvie Negrier; Motohide Uemura; Jae L Lee; Aleksandr Vasiliev; Wilson H Miller; Howard Gurney; Manuela Schmidinger; James Larkin; Michael B Atkins; Jens Bedke; Boris Alekseev; Jing Wang; Mariangela Mariani; Paul B Robbins; Aleksander Chudnovsky; Camilla Fowst; Subramanian Hariharan; Bo Huang; Alessandra di Pietro; Toni K Choueiri Journal: N Engl J Med Date: 2019-02-16 Impact factor: 91.245
Authors: Axel Bex; Peter Mulders; Michael Jewett; John Wagstaff; Johannes V van Thienen; Christian U Blank; Roland van Velthoven; Maria Del Pilar Laguna; Lori Wood; Harm H E van Melick; Maureen J Aarts; J B Lattouf; Thomas Powles; Igle Jan de Jong Md PhD; Sylvie Rottey; Bertrand Tombal; Sandrine Marreaud; Sandra Collette; Laurence Collette; John Haanen Journal: JAMA Oncol Date: 2019-02-01 Impact factor: 31.777